Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athersys Inc ATHXQ

Healthcare Biotechnology
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead... see more

Recent & Breaking News (GREY:ATHXQ)

Athersys Joins Russell 3000® Index

GlobeNewswire June 27, 2016

Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma

PR Newswire May 20, 2016

Athersys Reports First Quarter 2016 Results

GlobeNewswire May 5, 2016

Athersys to Host First Quarter Financial Results Call

GlobeNewswire April 18, 2016

Athersys to Present at Alliance for Regenerative Medicine's 4th Annual Cell & Gene Therapy Investor Day in New York

GlobeNewswire March 18, 2016

These Small Cap Plays Could Be Poised To Double - Here's Why

Accesswire March 15, 2016

Trending Stocks to Watch on Monday March 14, 2016

Accesswire March 14, 2016

Four Biotechs To Consider On Intermediate Bottom, Trend Change Signal

Accesswire March 14, 2016

Best Stocks to Buy for March 2016, If You So Choose

Accesswire March 11, 2016

Athersys Reports Fourth Quarter and 2015 Annual Results

GlobeNewswire March 10, 2016

3 Stocks That Should be in Your Portfolio Today

Accesswire February 26, 2016

3 Biotech Stocks to Consider Buying Right Now

Accesswire February 25, 2016

Why These Small Caps Could Be Massively Undervalued

Accesswire February 19, 2016

One-Year Results From Phase 2 Stroke Study of MultiStem® Cell Therapy Demonstrate a Significantly Higher Rate of Complete or Nearly Full Recovery

GlobeNewswire February 17, 2016

Athersys' MultiStem® Data to be Presented at International Stroke Conference 2016

GlobeNewswire February 10, 2016

Athersys to Host Year End 2015 Financial Results Call

GlobeNewswire February 9, 2016

Athersys to Present at 18th Annual BIO CEO & Investor Conference

GlobeNewswire February 1, 2016

Athersys and Healios Announce R&D Day

GlobeNewswire January 26, 2016

Publication Provides Further Confirmation of the Potential for Athersys' MultiStem® Cell Therapy to Provide Benefit in Acute Neurological Injury

GlobeNewswire January 13, 2016

Athersys, Inc. (NASDAQ: ATHX) to Receive License Fee of $15 million

Accesswire January 11, 2016